Treatment-resistant depression: what it means and what can help

You’ve tried antidepressants. Perhaps more than once. Perhaps several different ones, at different doses, over months or years. And yet here you are, still struggling. Still not feeling like yourself.

If this is your experience, there is a clinical explanation — and more importantly, there is a clinically proven next step. This article explains what treatment-resistant depression actually means, why it happens, and what the evidence says about the options available to you right now.

You are not treatment-resistant as a person. Your brain simply hasn’t yet found the right treatment.

What is treatment-resistant depression?

Treatment-resistant depression, often abbreviated to TRD, is defined clinically as depression that has not responded adequately to at least two antidepressant trials — at appropriate doses, taken for an adequate duration (typically six to eight weeks each).

It is far more common than many people realise. Research consistently shows that around one in three people with depression do not achieve full remission from their first antidepressant. After two failed trials, that number rises further. The landmark STAR-D study — the largest antidepressant trial ever conducted — found that only 28–32% of patients achieved remission from a first course of antidepressants. With each subsequent medication switch, the chances of success declined.

This is not a reflection of personal weakness, lack of effort, or severity of character. It is a neurological reality. For a significant proportion of people with depression, the chemical approach that antidepressants offer simply does not address the underlying mechanism driving their symptoms.

Why do antidepressants not work for everyone?

Depression is not one single condition. It is a broad clinical category that can arise from different neurological, genetic, hormonal, and environmental causes. Antidepressants are designed to address one aspect of this — the balance of neurotransmitters like serotonin and noradrenaline — but in some people, the dominant driver of depression lies elsewhere.

Neurological differences

In treatment-resistant depression, brain imaging research consistently shows underactivity in specific regions — particularly the dorsolateral prefrontal cortex (DLPFC), which is responsible for mood regulation, executive function, and emotional processing. This underactivity doesn’t respond well to chemical intervention alone.

Medication tolerance and resistance

Some patients develop tolerance to antidepressants over time. Others carry genetic variations affecting how their liver metabolises medication — meaning standard doses may produce far higher or lower blood concentrations than intended, explaining why a medication that works for one person does nothing for another.

Inadequate dosing or duration

In some cases, previous treatment courses have been too short or at sub-therapeutic doses. While this is distinct from true treatment resistance, it produces the same outcome for the patient: no improvement, and mounting frustration.

Whatever the cause, the clinical reality is the same: if two or more antidepressant trials have not produced adequate relief, continuing to try further medications in the same class offers diminishing returns. This is the point at which a different approach becomes not just reasonable, but recommended.

The emotional reality of treatment-resistant depression

Beyond the clinical definition, treatment-resistant depression carries a particular emotional weight that medication-responsive depression does not. Patients who have been through multiple medication trials often describe a compounding sense of hopelessness — not just about their depression, but about the possibility of ever feeling better.

“I’ve tried everything. Nothing works. Maybe nothing ever will.” This is one of the most common things we hear from patients when they first contact us — and it is almost never true.

Many patients have spent years in the NHS system, seeing their GP, trying different medications, attending IAPT services. They have been told to wait. They have been referred and re-referred. They have struggled through medication side effects that made them feel worse, not better: weight gain, emotional numbness, reduced libido, fatigue.

If this is your experience, we want to be direct with you: having tried multiple antidepressants without success does not mean your depression cannot be treated. It means the different treatment strategy is required. That is a meaningful and important distinction.

What are the evidence-based options for treatment-resistant depression?

Several approaches have a strong evidence base specifically for treatment-resistant depression. These include:

• Augmentation strategies: adding lithium, atypical antipsychotics, or other agents to an existing antidepressant. Effective for some patients but requires close monitoring and carries its own side effect profile.
• Electroconvulsive treatment (ECT): highly effective for severe depression but requires general anaesthesia and is associated with temporary memory impairment. It carries the risk of side effects of general anaesthesia.
• Ketamine/esketamine: a newer approach with rapid antidepressant effects, but with limited availability in the UK, significant cost, and ongoing questions about long-term use.
• Repetitive Transcranial Magnetic Stimulation (rTMS): NICE-approved since 2015 for treatment-resistant depression. Non-invasive, medication-free, no anaesthesia, no memory effects, compatible with existing medication. An increasingly recommended first-line option for TRD.

Of these, rTMS stands out as the option combining the strongest safety profile with strong clinical evidence and minimal practical barriers to treatment.

How rTMS addresses treatment-resistant depression

Where antidepressants attempt to alter brain chemistry systemically, rTMS acts directly on the neural circuits involved in mood regulation. Targeted magnetic pulses stimulate the underactive dorsolateral prefrontal cortex, encouraging nerve cells to fire more regularly and rebuilding the connectivity that depression disrupts.

This neurological approach works on a different axis to antidepressants entirely — which is precisely why it succeeds for many patients who have not responded to medication. It is not a stronger version of the same thing. It is something categorically different.

In our own published research at Tranquil TMS, conducted across our UK patient cohort and published in the Journal of Psychiatry Depression & Anxiety in 2020, we recorded a response rate of 66.66% and a remission rate of 37.03% — in a population that had already not responded to antidepressants.

66–76% of our patients respond positively

1 in 3 achieve full remission

That response rate is more than double the 28–32% seen with antidepressants in treatment-resistant populations. rTMS does not work for everyone. But it works for the majority — including many who had lost hope of ever feeling better.

What to do if you think you have treatment-resistant depression

If you have tried two or more antidepressants without adequate improvement, or if your depression has significantly reduced your ability to work, maintain relationships, or enjoy life, it is worth exploring rTMS as a next step.

You do not need a GP referral to contact us. We offer a free initial telephone call for 20 minutes with one of our Senior Consultant Psychiatrists, during which we will try to answer your questions, and let you know whether rTMS is likely to be appropriate for you.

Appointments for assessment are typically available within one to two weeks. Treatment can begin shortly after.